Nature’s Sunshine Products ((NATR)) announced an update on their ongoing clinical study.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Nature’s Sunshine Products is conducting a study titled ‘Evaluation of Acute Cognitive Effects of Brain Edge on Healthy Volunteers.’ The study aims to assess the cognitive benefits of Brain Edge, a dietary supplement, on healthy adults. This research is significant as it explores potential enhancements in cognitive health and mood.
The intervention being tested is Brain Edge, a supplement made from herbs, vitamins, and amino acids, designed to support cognitive function. Participants will receive either Brain Edge or a placebo in a controlled setting.
The study is a double-blind, placebo-controlled, crossover trial involving 50 participants. It is randomized, with both participants and care providers blinded to the interventions, aiming to ensure unbiased results.
The study was first submitted on May 14, 2025, with the last update on June 10, 2025. It has not yet begun recruiting, indicating that the study’s findings are still pending.
For investors, this study could influence Nature’s Sunshine Products’ stock performance, as positive results may enhance the company’s market position in the cognitive health sector. Competitors in the dietary supplement industry will be watching closely.
The study is ongoing, with further details available on the ClinicalTrials portal.